X

Trial Profile

Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aspirin (Primary) ; Enoxaparin sodium (Primary) ; Heparin (Primary) ; Ticagrelor (Primary)
Indications Acute coronary syndromes
Focus Proof of concept; Therapeutic Use
Acronyms EROSION

Most Recent Events

06 May 2022 Results of an analysis assessed the evolution of hemodynamic parameters on the plaque erosion site in conservatively treated patients published in the International Journal of Cardiology
28 Oct 2016 New trial record
30 Aug 2016 Primary endpoint (Reduction of thrombus burden by OCT) has been met, according to results published in the European Heart Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com